XML 58 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Additional Information (Detail)
3 Months Ended 12 Months Ended
Mar. 31, 2018
USD ($)
CommercialTest
shares
Mar. 27, 2018
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Transfers between Level 1, Level 2 and Level 3 categories during the periods $ 0     $ 0
Change in estimated fair value of contingent consideration $ 144,000   $ (221,000)  
Change in fair market value of derivative liability   $ 2,500,000 800,000  
ImmuMetrix, Inc. [Member] | Contingent Consideration Liability [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Contingent obligation to issue common stock | shares 227,845     227,845
Milestone description The issuance of shares will occur if the Company completes 2,500 commercial tests involving the measurement of dd-cfDNA in organ transplant recipients in the United States by June 10, 2020.      
Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTest 2,500      
Change in estimated fair value of contingent consideration $ 100,000   $ (200,000)  
ImmuMetrix, Inc. [Member] | Minimum [Member] | Contingent Consideration Liability [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Percentage of probability in achieving contingency condition 80.00%      
ImmuMetrix, Inc. [Member] | Maximum [Member] | Contingent Consideration Liability [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Percentage of probability in achieving contingency condition 100.00%